Diabetic Nephropathy Market Research, 2031
The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.
Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It occurs when high blood glucose levels damages kidney functions. It can occur in people with type-2 diabetes. Diabetic nephropathy is caused by damage to the tiniest blood vessels. When small blood vessels begin to develop damage, both kidneys begin to leak proteins into the urine. As damage to the blood vessels continues, the kidneys gradually lose their ability to remove waste products from the blood. It occurs when high blood glucose levels damage kidney function. Up to 40% of people with type-1 diabetes eventually develop significant kidney diseases, which sometimes requires dialysis or a kidney transplant. Only 4 to 6 % of all type-2 diabetes patients end up requiring dialysis, although about 20–30% of people with type-2 diabetes develop at least some kidney damage. About 40% of all people who need to start dialysis have kidney failure from type-1 or type-2 diabetes.
The diabetic nephropathy is diagnosed by different test such as urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR), and other special tests includes imaging tests (CT scanning, MRI) and Kidney biopsy.
The major factors that drive the diabetic nephropathy market is surge in number of geriatric populations suffering from diabetic nephropathy, continuous increase in range of conditions that can be treated by diabetic nephropathy medicine and rise in demand of anti-diabetic medicine. This market also increased due to rise in incidence rates of various kidney diseases and rise in testing, which are expected to offer lucrative opportunities for market expansion.
Diabetic nephropathy can be controlled by taking medication, low protein diet, adopt healthy lifestyle, exercise and proper checkup that are preventing from kidney failure. Furthermore, diabetic nephropathy medicine work by controlling the blood glucose level, lowering cholesterol level and lowering to high blood pressure (hypertension). Due to wide application of diabetic nephropathy medicine and increasing the diagnostic tests of diabetic nephropathy are led to the growth of diabetic nephropathy market share. Moreover, increase in initiatives by governments & non-governmental organizations to promote awareness about diabetic nephropathy significantly contributes toward the growth of the industry.
However, the sales of diabetic nephropathy medicine have witnessed hindrances, owing to lack of skilled professionals for treatment of diabetic nephropathy in emerging and less developed countries, poor planning of diabetic nephropathy treatment in low-income countries are the key factors restraining the market. Strict regulatory rules regarding selling and lengthy approval time for drugs for diabetic nephropathy are also hamper the market growth. Due to these factors, the sales of premium diabetic nephropathy product are minimum. Conversely, the introduction of new medicine of diabetic nephropathy into developing nations is anticipated to offer remunerative opportunities for the expansion of the global market during the forecast period.
Furthermore, the healthcare business in developing nations is predicted to grow significantly as a result of various reasons, including increased investment in both the public and private sectors, rise in chronic diseases, surge in number of diabetes cases, and population expansion. Furthermore, an increase in healthcare spending is expected to promote the expansion of the healthcare business, which, in turn, is expected to fuel product demand.
The significant reduction in clinical trials due to strict government guidelines against COVID-19. Dialysis and transplant of kidney operation in diabetic nephropathy patient were postponed and home care setting care was preferred. Furthermore, the lockdown led to the disruption of manufacturing and transportation of healthcare essentials. According to FDA data that was published in 2019, approximately 40% pharmaceutical manufacturing unit established in India and China for the active pharmaceutical ingredient. Therefore, it has severely impacted to the supply chain of drugs.
The diabetic nephropathy market is segmented into Drugs Class, Type and Distribution Channel.
On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor and others. By type, the market is segregated into type-1 diabetes, & type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug & retail pharmacy.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)
Segment Review
Depending on drug class, in diabetic nephropathy market size, the angiotensin-converting enzyme inhibitors segment was the highest revenue contributor in the global market in 2021, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR of 7.4% during the forecast period owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.
By Drugs Class
Diuretics segment was the leading segment during forecast period.
On the basis of type of diabetic nephropathy, the type-2 diabetes segment generated maximum revenue in 2021, owing to surge in diabetes cases and increase in awareness and diagnosis of diabetic nephropathy. The type-2 diabetes segment is also expected to witness highest CAGR during the diabetic nephropathy market forecast period.
By Type
Type-2 Diabetes segment dominates the South Africa Diabetic nephropathy Market and is expected to retain its dominance throughout the forecast period.
On the basis of distribution channel, in diabetic nephropathy market size, the drug stores & retail pharmacy segment was the highest revenue contributor to the market in 2021. The online providers segment is expected to witness highest CAGR during the forecast period, owing to increase in population suffering from diabetes and geriatric population.
By Distribution Channel
Online Providers segment is projected to be the dominating segment throughout the forecast period.
Depending on region, the North America generated maximum revenue in 2021, owing to increase in the number of patient admissions, and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.
By Region
North America held the largest market share in 2021
The key players operating in the diabetic nephropathy industry are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and diabetic nephropathy market growth strategies.
Diabetic nephropathy Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 3.3 billion |
 Growth Rate | CAGR of 6% |
 Forecast period | 2021 - 2031 |
 Report Pages | 266 |
 By Distribution Channel |
|
 By Drugs Class |
|
 By Type |
|
 By Region |
|
 Key Market Players | Astrazenica Plc, Eli Lilly and Company, Abbott Laboratories, Bayer AG, Merck & Co, Pfizer Inc., Novartis AG, AbbVie Inc., Reata Pharmaceuticals, Sanofi |
Analyst Review
This section provides opinions of top level CXOs in the diabetic nephropathy market. According to insights of CXOs, diabetic nephropathy is gaining high traction in the market, owing to increase in prevalence of diabetes and obesity, rise in R&D investments in drug discovery & development, and increase in awareness regarding diabetes & kidney-related disorders. Furthermore, key players in the market are focusing on adopting strategies to increase accessibility and utilization of diabetic nephropathy products in developing economies.
CXOs further added that diabetic nephropathy medicines provide relief from inflammation and help in lowering blood glucose level and preventing from chronic renal disease. Anti-diabetic nephropathy medicine is also lower to cholesterol level and maintaining blood pressure. Furthermore, experts of key companies believe surge in geriatric population, which is more prone to diabetic nephropathy diseases that require advanced treatment such as dialysis and transplant and rise in cases of diabetic nephropathy in adults may require temporary or permanent diabetic nephropathy treatment, thus increasing utilization of medicines. The market gains interest of healthcare companies, owing to its unmet demands in developing economies such as India and China where the population is growing rapidly along with diabetes load.
North America is expected to witness highest growth, in terms of revenue, owing to increase in cases of diabetes, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in geriatric population, unmet medical demands, initiatives by government & non-governmental organizations (NGOs) to promote awareness regarding diabetic nephropathy, and increase in public–private investments in the healthcare sector
The total market value of Diabetic Nephropathy is $3,338.5 million in 2031.
Top companies such as Abbott Laboratories, AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc.. held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in U.S., Europe and LAMEA.
The diuretics segment is the most influencing segment owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.
The forecast period for Diabetic Nephropathy is 2022 to 2031.
The market value of Diabetic Nephropathy in 2021 is $1,863.17 million.
Yes, the Diabetic Nephropathy report provides PORTER Analysis.
The base year is 2021 in Diabetic Nephropathy.
Loading Table Of Content...
Loading Research Methodology...
